Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management

Pediatric Transplantation

Volumn 20, Issue 6, 2016, Pages 756-769

  Oishi, Kimihiko ^a   Arnon, Ronen ^a,b   Wasserstein, Melissa P ^a   Diaz, George A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

inborn errors of metabolism; long term follow up; pediatric liver transplantation; perioperative management

Indexed keywords

ACUTE INTERMITTENT PORPHYRIA; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANESTHESIOLOGICAL PROCEDURE; ARGININOSUCCINIC ACIDURIA; CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY; CITRULLINEMIA; CRIGLER NAJJAR SYNDROME; DIET RESTRICTION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ERYTHROPOIETIC PROTOPORPHYRIA; FAMILIAL HYPERCHOLESTEROLEMIA; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 4; HUMAN; HYPERARGININEMIA; INBORN ERROR OF METABOLISM; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE; METABOLIC DISORDER; METHYLMALONIC ACIDEMIA; NEUROPATHY; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; OXALOSIS 1; PERIOPERATIVE PERIOD; PHOTOTOXICITY; POSTOPERATIVE COMPLICATION; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; PROPIONIC ACIDEMIA; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; TYROSINEMIA; TYROSINEMIA TYPE 1; WILSON DISEASE;

EID: 84983385841     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12741     Document Type: Review

References (150)

1. Largilliere C, Houssin D, Gottrand F, et al. Liver transplantation for ornithine transcarbamylase deficiency in a girl. J Pediatr 1989: 115: 415–417.
2. Mowat AP. Liver disorders in children: The indications for liver replacement in parenchymal and metabolic diseases. Transplant Proc 1987: 19: 3236–3241.
3. Camp KM, Parisi MA, Acosta PB, et al. Phenylketonuria Scientific Review Conference: State of the science and future research needs. Mol Genet Metab 2014: 112: 87–122.
4. Arnon R, Kerkar N, Davis MK, et al. Liver transplantation in children with metabolic diseases: The studies of pediatric liver transplantation experience. Pediatr Transplant 2010: 14: 796–805.
5. Shneider BL, Vockley J, Mazariegos GV. Trading places: Liver transplantation as a treatment, not a cure, for metabolic liver disease. Liver Transpl 2011: 17: 628–630.
6. Miloh T. Medical management of children after liver transplantation. Curr Opin Organ Transplant 2014: 19: 474–479.
7. Kwong AJ, Fix OK. Update on the management of the liver transplant patient. Curr Opin Gastroenterol 2015: 31: 224–232.
8. Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr 1998: 68: 72–81.
9. Kasahara M, Sakamoto S, Horikawa R, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: The Japanese multicenter registry. Pediatr Transplant 2014: 18: 6–15.
10. Sniderman King L, Trahms C, Scott CR. [Updated 2014 Jul 17]. Tyrosinemia type I. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2013. Available at http://www.genetests.org.
11. Mohan N, McKiernan P, Preece MA, et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999: 158(Suppl 2): S49–S54.
12. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992: 340: 813–817.
13. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006: 66: 743–750.
14. Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 2008: 9: 1229–1236.
15. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 2008: 31: 399–402.
16. Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 2013: 36: 15–20.
17. Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. J Inherit Metab Dis 2005: 28: 871–876.
18. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993: 5: 327–337.
19. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993: 5: 344–350.
20. Davies KM, Hare DJ, Cottam V, et al. Localization of copper and copper transporters in the human brain. Metallomics 2013: 5: 43–51.
21. Aggarwal A, Bhatt M. Update on Wilson disease. Int Rev Neurobiol 2013: 110: 313–348.
22. Schilsky ML. Liver transplantation for Wilson's disease. Ann N Y Acad Sci 2014: 1315: 45–49.
23. Catana AM, Medici V. Liver transplantation for Wilson disease. World J Hepatol 2012: 4: 5–10.
24. Stracciari A, Tempestini A, Borghi A, Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 2000: 57: 384–386.
25. Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson's disease: Experience in France. J Hepatol 2014: 60: 579–589.
26. Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005: 11: 1056–1063.
27. Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep 2014: 16: 367.
28. Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. Liver Transpl 2013: 19: 1370–1376.
29. Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology 2014: 60: 1082–1089.
30. Balwani M, Desnick RJ. The porphyrias: Advances in diagnosis and treatment. Blood 2012: 120: 4496–4504.
31. Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004: 363: 705–706.
32. Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol 2005: 19: 235–249.
33. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005: 142: 439–450.
34. Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl 2012: 18: 195–200.
35. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol 2012: 65: 976–980.
36. Frei P, Minder EI, Corti N, et al. Liver transplantation because of acute liver failure due to heme arginate overdose in a patient with acute intermittent porphyria. Case Rep Gastroenterol 2012: 6: 190–196.
37. Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 2010: 23: e18–e21.
38. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000: 248: 319–325.
39. Wells MM, Golitz LE, Bender BJ. Erythropoietic protoporphyria with hepatic cirrhosis. Arch Dermatol 1980: 116: 429–432.
40. McGuire BM, Bonkovsky HL, Carithers RL Jr, et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005: 11: 1590–1596.
41. Wahlin S, Stal P, Adam R, et al. Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transpl 2011: 17: 1021–1026.
42. Herbert A, Corbin D, Williams A, Thompson D, Buckels J, Elias E. Erythropoietic protoporphyria: Unusual skin and neurological problems after liver transplantation. Gastroenterology 1991: 100: 1753–1757.
43. Rank JM, Carithers R, Bloomer J. Evidence for neurological dysfunction in end-stage protoporphyric liver disease. Hepatology 1993: 18: 1404–1409.
44. Strauss KA, Puffenberger EG, Morton DH. [Updated 2013 May 9]. Maple syrup urine disease. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle, 1997–1997. Available at http://www.genetests.org.
45. Mazariegos GV, Morton DH, Sindhi R, et al. Liver transplantation for classical maple syrup urine disease: Long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012: 160: 116–121 e111.
46. Strauss KA, Mazariegos GV, Sindhi R, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant 2006: 6: 557–564.
47. Delaney A, Gal TJ. Hazards of anesthesia and operation in maple-syrup-urine disease. Anesthesiology 1976: 44: 83–86.
48. Kahraman S, Ercan M, Akkus O, Ercelen O, Erdem K, Coskun T. Anaesthetic management in maple syrup urine disease. Anaesthesia 1996: 51: 575–578.
49. Fuentes-Garcia D, Falcon-Arana L. Perioperative management of a patient with maple syrup urine disease. Br J Anaesth 2009: 102: 144–145.
50. Ah Mew N, Lanpher BC, Gropman A, et al. (Updated 2015 Apr 9). Urea cycle disorders overview. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle, 1997–2013. Available at http://www.genetests.org.
51. Kim IK, Niemi AK, Krueger C, et al. Liver transplantation for urea cycle disorders in pediatric patients: A single-center experience. Pediatr Transplant 2013: 17: 158–167.
52. Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004: 81(Suppl 1): S74–S78.
53. Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: A review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl 2005: 11: 1332–1342.
54. Wakiya T, Sanada Y, Mizuta K, et al. Living donor liver transplantation for ornithine transcarbamylase deficiency. Pediatr Transplant 2011: 15: 390–395.
55. Hasegawa T, Tzakis AG, Todo S, et al. Orthotopic liver transplantation for ornithine transcarbamylase deficiency with hyperammonemic encephalopathy. J Pediatr Surg 1995: 30: 863–865.
56. Silva ES, Cardoso ML, Vilarinho L, Medina M, Barbot C, Martins E. Liver transplantation prevents progressive neurological impairment in argininemia. JIMD Rep 2013: 11: 25–30.
57. Wakiya T, Sanada Y, Urahashi T, et al. Living donor liver transplantation from an asymptomatic mother who was a carrier for ornithine transcarbamylase deficiency. Pediatr Transplant 2012: 16: E196–E200.
58. Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001: 138: S30–S39.
59. Busuttil AA, Goss JA, Seu P, et al. The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. Liver Transpl Surg 1998: 4: 350–354.
60. Kasahara M, Sakamoto S, Shigeta T, et al. Living-donor liver transplantation for carbamoyl phosphate synthetase 1 deficiency. Pediatr Transplant 2010: 14: 1036–1040.
61. Chou JY, Jun HS, Mansfield BC. Glycogen storage disease type I and G6Pase-beta deficiency: Etiology and therapy. Nat Rev Endocrinol 2010: 6: 676–688.
62. Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999: 158(Suppl 2): S43–S48.
63. Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: Controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008: 12: 137–145.
64. Selby R, Starzl TE, Yunis E, et al. Liver transplantation for type I and type IV glycogen storage disease. Eur J Pediatr 1993: 152(Suppl 1): S71–S76.
65. Sokal EM, Van Hoof F, Alberti D, de Ville de Goyet J, de Barsy T, Otte JB. Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis. Eur J Pediatr 1992: 151: 200–203.
66. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993: 152(Suppl 1): S63–S70.
67. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: A series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997: 24: 276–279.
68. Boers SJ, Visser G, Smit PG, Fuchs SA. Liver transplantation in glycogen storage disease type I. Orphanet J Rare Dis 2014: 9: 47.
69. Karaki C, Kasahara M, Sakamoto S, et al. Glycemic management in living donor liver transplantation for patients with glycogen storage disease type 1b. Pediatr Transplant 2012: 16: 465–470.
70. Kasahara M, Horikawa R, Sakamoto S, et al. Living donor liver transplantation for glycogen storage disease type Ib. Liver Transpl 2009: 15: 1867–1871.
71. Alsultan A, Sokol RJ, Lovell MA, Thurman G, Ambruso DR. Long term G-CSF-induced remission of ulcerative colitis-like inflammatory bowel disease in a patient with glycogen storage disease Ib and evaluation of associated neutrophil function. Pediatr Blood Cancer 2010: 55: 1410–1413.
72. Couper R, Kapelushnik J, Griffiths AM. Neutrophil dysfunction in glycogen storage disease Ib: Association with Crohn's-like colitis. Gastroenterology 1991: 100: 549–554.
73. Yamaguchi T, Ihara K, Matsumoto T, et al. Inflammatory bowel disease-like colitis in glycogen storage disease type 1b. Inflamm Bowel Dis 2001: 7: 128–132.
74. Guven AG, Koyun M, Artan R, Dursun O, Baysal YE, Akman S. Severe lactic acidosis and nephrolithiasis in an infant–etiology?: Type 1 glycogen storage disease (GSD). Pediatr Nephrol 2006: 21: 761–765.
75. Reddy SK, Kishnani PS, Sullivan JA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol 2007: 47: 658–663.
76. Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002: 161(Suppl 1): S112–S119.
77. Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996: 98: 352–357.
78. Shimizu J, Shiraishi H, Sakurabayashi S, et al. A report on an adult case of type III glycogenosis with primary liver cancer and liver cirrhosis. Nihon Shokakibyo Gakkai Zasshi 1982: 79: 2328–2332.
79. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med 1993: 328: 745–749.
80. Choleva AJ. Anesthesia considerations in a patient with McArdle disease: A case report. AANA J 2011: 79: 243–247.
81. De Armendi A, Patel V, Mayhew JF. Anesthetic management in a child with Glycogen Storage Disease IV. Paediatr Anaesth 2010: 20: 475.
82. Mohart D, Russo P, Tobias JD. Perioperative management of a child with glycogen storage disease type III undergoing cardiopulmonary bypass and repair of an atrial septal defect. Paediatr Anaesth 2002: 12: 649–654.
83. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: Diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002: 161(Suppl 1): S20–S34.
84. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931–940.
85. Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992: 90: 150–155.
86. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006: 165: 306–319.
87. Schauer R, Stangl M, Lang T, et al. Treatment of Crigler-Najjar type 1 disease: Relevance of early liver transplantation. J Pediatr Surg 2003: 38: 1227–1231.
88. Shanmugam NP, Perumalla R, Gopinath R, et al. Auxiliary liver transplantation: A form of gene therapy in selective metabolic disorders. J Clin Exp Hepatol 2011: 1: 118–120.
89. Prager MC, Johnson KL, Ascher NL, Roberts JP. Anesthetic care of patients with Crigler-Najjar syndrome. Anesth Analg 1992: 74: 162–164.
90. Robards C, Brull SJ. The anesthetic implications of Crigler-Najjar syndrome. Anesth Analg 2007: 104: 435–436.
91. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013: 369: 649–658.
92. Morgan SH, Purkiss P, Watts RW, Mansell MA. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. Nephron 1987: 46: 253–257.
93. Strobele B, Loveland J, Britz R, Gottlich E, Welthagen A, Botha J. Combined paediatric liver-kidney transplantation: Analysis of our experience and literature review. S Afr Med J 2013: 103: 925–929.
94. Cochat P, Gaulier JM, Koch Nogueira PC, et al. Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur J Pediatr 1999: 158(Suppl 2): S75–S80.
95. Jamieson NV. The results of combined liver/kidney transplantation for primary hyperoxaluria (PH1) 1984-1997. The European PH1 transplant registry report. European PH1 Transplantation Study Group. J Nephrol 1998: 11(Suppl 1): 36–41.
96. Cochat P, Scharer K. Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1? Pediatr Nephrol 1993: 7: 212–218; discussion 218–219.
97. Sasaki K, Sakamoto S, Uchida H, et al. Two-step transplantation for primary hyperoxaluria: A winning strategy to prevent progression of systemic oxalosis in early onset renal insufficiency cases. Pediatr Transplant 2015: 19: E1–E6.
98. Compagnon P, Metzler P, Samuel D, et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: The French experience. Liver Transpl 2014: 20: 1475–1485.
99. Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: A review of the liver pathology findings. Semin Liver Dis 2011: 31: 3–10.
100. Harris MJ, Le Couteur DG, Arias IM. Progressive familial intrahepatic cholestasis: Genetic disorders of biliary transporters. J Gastroenterol Hepatol 2005: 20: 807–817.
101. Ismail H, Kalicinski P, Markiewicz M, et al. Treatment of progressive familial intrahepatic cholestasis: Liver transplantation or partial external biliary diversion. Pediatr Transplant 1999: 3: 219–224.
102. Schukfeh N, Metzelder ML, Petersen C, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 2012: 47: 501–505.
103. Aydogdu S, Cakir M, Arikan C, et al. Liver transplantation for progressive familial intrahepatic cholestasis: Clinical and histopathological findings, outcome and impact on growth. Pediatr Transplant 2007: 11: 634–640.
104. Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation 2007: 84: 1361–1363.
105. Maggiore G, Gonzales E, Sciveres M, et al. Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2. J Hepatol 2010: 53: 981–986.
106. Jara P, Hierro L, Martinez-Fernandez P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009: 361: 1359–1367.
107. Kubitz R, Droge C, Kluge S, et al. Autoimmune BSEP disease: Disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis. Clin Rev Allergy Immunol 2015: 48: 273–284.
108. Stindt J, Kluge S, Droge C, et al. Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced BSEP deficiency. Hepatology 2015: 63: 524–537.
109. Lin HC, Alvarez L, Laroche G, et al. Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation. Liver Transpl 2013: 19: 1403–1410.
110. Varghese MJ. Familial hypercholesterolemia: A review. Ann Pediatr Cardiol 2014: 7: 107–117.
111. Youngblom E, Knowles JW. (2014 Jan 2). Familial hypercholesterolemia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2013. Available at http://www.genetests.org.
112. Page MM, Ekinci EI, Jones RM, Angus PW, Gow PJ, O'Brien RC. Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Intern Med J 2014: 44: 601–604.
113. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol 2013: 24: 288–294.
114. Kawagishi N, Satoh K, Akamatsu Y, et al. Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. J Atheroscler Thromb 2007: 14: 94–98.
115. Ibrahim M, El-Hamamsy I, Barbir M, Yacoub MH. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J Cardiovasc Transl Res 2012: 5: 351–358.
116. Alkofer BJ, Chiche L, Khayat A, et al. Liver transplant combined with heart transplant in severe heterozygous hypercholesterolemia: Report of the first case and review of the literature. Transplant Proc 2005: 37: 2250–2252.
117. Mazariegos G, Shneider B, Burton B, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab 2014: 111: 418–427.
118. Carrillo-Carrasco N, Venditti C. Propionic acidemia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2013. Available at http://www.genetests.org.
119. Manoli I, Sloan JL, Venditti CP. (Updated 2016 Jan 7). Methylmalonic acidemia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2013. Available at http://www.genetests.org.
120. Mc Guire PJ, Lim-Melia E, Diaz GA, et al. Combined liver-kidney transplant for the management of methylmalonic aciduria: A case report and review of the literature. Mol Genet Metab 2008: 93: 22–29.
121. Romano S, Valayannopoulos V, Touati G, et al. Cardiomyopathies in propionic aciduria are reversible after liver transplantation. J Pediatr 2010: 156: 128–134.
122. Barshes NR, Vanatta JM, Patel AJ, et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: A comprehensive review. Pediatr Transplant 2006: 10: 773–781.
123. Chao PW, Chang WK, Lai IW, Liu C, Chan KH, Tsao CM. Acute life-threatening arrhythmias caused by severe hyperkalemia after induction of anesthesia in an infant with methylmalonic acidemia. J Chin Med Assoc 2012: 75: 243–245.
124. Nagarajan S, Enns GM, Millan MT, Winter S, Sarwal MM. Management of methylmalonic acidaemia by combined liver-kidney transplantation. J Inherit Metab Dis 2005: 28: 517–524.
125. Kamei K, Ito S, Shigeta T, et al. Preoperative dialysis for liver transplantation in methylmalonic acidemia. Ther Apher Dial 2011: 15: 488–492.
126. Saudubray JM, Touati G, Delonlay P, et al. Liver transplantation in propionic acidaemia. Eur J Pediatr 1999: 158(Suppl 2): S65–S69.
127. Chen PW, Hwu WL, Ho MC, et al. Stabilization of blood methylmalonic acid level in methylmalonic acidemia after liver transplantation. Pediatr Transplant 2010: 14: 337–341.
128. Kasahara M, Horikawa R, Tagawa M, et al. Current role of liver transplantation for methylmalonic acidemia: A review of the literature. Pediatr Transplant 2006: 10: 943–947.
129. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med 2012: 366: 1132–1141.
130. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012: 4: CD004426.
131. Avula S, Parikh S, Demarest S, Kurz J, Gropman A. Treatment of mitochondrial disorders. Curr Treat Options Neurol 2014: 16: 292.
132. Lee WS, Sokol RJ. Mitochondrial hepatopathies: Advances in genetics, therapeutic approaches, and outcomes. J Pediatr 2013: 163: 942–948.
133. Cormier-Daire V, Chretien D, Rustin P, et al. Neonatal and delayed-onset liver involvement in disorders of oxidative phosphorylation. J Pediatr 1997: 130: 817–822.
134. Dimmock DP, Dunn JK, Feigenbaum A, et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transpl 2008: 14: 1480–1485.
135. Sokal EM, Sokol R, Cormier V, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999: 158(Suppl 2): S81–S84.
136. Niezgoda J, Morgan PG. Anesthetic considerations in patients with mitochondrial defects. Paediatr Anaesth 2013: 23: 785–793.
137. Parikh S, Saneto R, Falk MJ, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009: 11: 414–430.
138. Patel N, Loveland J, Zuckerman M, Moshesh P, Britz R, Botha J. Heterozygote to homozygote related living donor liver transplantation in maple syrup urine disease: A case report. Pediatr Transplant 2015: 19: E62–E65.
139. Feier FH, Miura IK, Fonseca EA, et al. Successful domino liver transplantation in maple syrup urine disease using a related living donor. Braz J Med Biol Res 2014: 47: 522–526.
140. Kadohisa M, Matsumoto S, Sawada H, et al. Living donor liver transplantation from a heterozygous parent for classical maple syrup urine disease. Pediatr Transplant 2015: 19: E66–E69.
141. Dutoit AP, Flick RR, Sprung J, Babovic-Vuksanovic D, Weingarten TN. Anesthetic implications of ornithine transcarbamylase deficiency. Paediatr Anaesth 2010: 20: 666–673.
142. Iida R, Nagai H, Iwasaki K, et al. Anesthetic management of a patient with ornithine transcarbamylase deficiency. Masui 1996: 45: 642–645.
143. Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S. Anesthetic management of patients with ornithine transcarbamylase deficiency. Paediatr Anaesth 2006: 16: 333–337.
144. Arcas-Bellas JJ, Arevalo-Ludena J, Onate ML, Aranzubia M, Alvarez-Rementeria R, Munoz-Alameda L. General anesthesia in an adult female with propionic acidemia: Anesthetic considerations. Minerva Anestesiol 2013: 79: 313–315.
145. Harker HE, Emhardt JD, Hainline BE. Propionic acidemia in a four-month-old male: A case study and anesthetic implications. Anesth Analg 2000: 91: 309–311.
146. Karagoz AH, Uzumcugil F, Celebi N, Canbay O, Ozgen S. Anesthetic management of a 2-year-old male with propionic acidemia. Paediatr Anaesth 2006: 16: 1290–1291.
147. Ozturk L, Kesimci E, Albayrak T, Kanbak O. Sevoflurane in anaesthetic management of a patient with methylmalonic acidaemia. Eur J Anaesthesiol 2011: 28: 143–145.
148. Sanchez-Rodenas L, Hernandez-Palazon J, Burguillos-Lopez S, Sanchez-Ortega JL, Castano-Collado I, Garcia-Ferreira J. Infant boy with propionic acidemia: Anesthetic implications. Rev Esp Anestesiol Reanim 2005: 52: 429–432.
149. Rocquelin G, Tapsoba S, Mbemba F, Gallon G, Picq C. Lipid content and fatty acid composition in foods commonly consumed by nursing Congolese women: Incidences on their essential fatty acid intakes and breast milk fatty acids. Int J Food Sci Nutr 1998: 49: 343–352.
150. Vater Y, Dembo G, Martay K, Klein Y, Vitin A, Weinbroum AA. Drug management in emergent liver transplantation of mitochondrial disorder carriers: Review of the literature. Clin Transplant 2010: 24: E43–E53.